News

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.

Novo Nordisk (NYSE:NVO) has rebranded globally as "Novo" and introduced the "Lasting Health Starts Now" platform. The group is rolling out an updated corporate culture program called "The Novo Way" to align employees with the new identity. Management is positioning the refreshed brand and culture as a foundation for broader efforts to support improved health outcomes worldwide. The Novo rebrand and "Lasting Health Starts Now" push only capture part of the story investors need to weigh. Take...

Novo Nordisk (NYSE:NVO) announced a corporate rebranding initiative under which it will use “Novo” as its everyday operating name while retaining Novo Nordisk A/S as its legal global company name. The pharmaceutical company also introduced a new tagline, “Lasting Health Starts Now,” alongside a cultural framework called “The Novo Way.

Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.

Eli Lilly (NYSE:LLY) has launched its oral weight-management and type 2 diabetes treatment Foundayo in the UK, making Britain the first European market where the drug is commercially available, the company said on Monday. Foundayo, chemically known as orforglipron, will initially be available through private prescriptions after receiving authorisation from the UK’s medicines regulator on August 10.

Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through Fangzhou's AI driven Internet hospital, targeting broader access for people living with diabetes. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform. Novo Nordisk, trading at DKK329.9 per share, is adding Kyinsu® to its portfolio at a time when...

By Rishika Sadam July 9 (Reuters) - Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, aiming to compete with daily-dose options on the market. 

The new unit will start with $2.5 billion to help companies choose and use AI tools.

The new company will focus on integrating enterprise AI, offering tailored support and protecting client data and intellectual property.

Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.

Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...

Novo Nordisk Foundation has launched CardioMetabolic Bridge, a pan-European initiative focused on translating cardiometabolic research into commercial therapies. The program targets new treatments for obesity, diabetes, and cardiovascular disease, with funding spread over six years and across multiple European countries. The effort aims to move early-stage academic work closer to clinical testing and potential commercial use. Novo Nordisk (CPSE:NOVO B) enters this development with the stock...

Novo Nordisk Owner Bets Big on Obesity Breakthroughs With New $69 Million Program

Novo Nordisk Foundation commits up to EUR 60 million for drug discovery projects

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli Lilly

Oral version targets broader access as GLP-1 demand grows

Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.